FOSTER CITY, Calif. & SHANGHAI, June 13 (Bernama-BUSINESS WIRE) —Terns Pharmaceuticals, Inc. today announced the initiation of a Phase 1 clinical trial of TERN-101, an farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepatitis (NASH). Initiation of the study in the US follows US Food and Drug Administration (FDA) clearance of the Investigational New Drug application for TERN-101 filed earlier this year.
“We’ve made significant progress this year, advancing the development of our lead program, TERN-101, as part of our dedicated approach to NASH, a condition with no existing treatment options,” said Erin Quirk, M.D., Chief Medical Officer of Terns. “We look forward to evaluating data from this trial later this year as we assess the potential benefits of TERN-101 in the treatment of NASH.”
